EMA Reflects on Coated Nanomedicines - - BioPharm International

ADVERTISEMENT

EMA Reflects on Coated Nanomedicines


The European Medicines Agency (EMA) has published a reflection paper on general issues regarding the development of coated nanomedicines. The paper addresses issues that may arise in the development of nanomedicines that have a coating, including the effect of the coating on stability and possible interactions with other molecules.

The reflection paper is one in a series of four guidance documents discussing nanomedicines. EMA’s Committee for Medicinal Products for Human Use began developing guidance on the development of new nanomedicines and nanosimilars in 2011.

Source: European Medicines Agency

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines

Click here